Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 9Breast Neoplasms 7Neoplasms 4Lymphoma 4Brain Neoplasms 4Lymphoma, Non-Hodgkin 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Lymphoma, B-Cell 2Liver Neoplasms 2Leukemia 2Head and Neck Neoplasms 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma in Situ 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vulvar Diseases 1Vasculitis 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Papillomavirus Infections 1Pancreatic Neoplasms 1Osteomyelitis 1Neurofibromatosis 1 1

Interventions

Cyclophosphamide 34fludarabine 25fludarabine phosphate 24Tacrolimus 24Mycophenolic Acid 23Whole-Body Irradiation 22Busulfan 15Methotrexate 12Melphalan 12Granulocyte Colony-Stimulating Factor 12Antilymphocyte Serum 12thymoglobulin 11Cyclosporine 11Stem Cell Transplantation 10Filgrastim 10Rituximab 9Thiotepa 7Peripheral Blood Stem Cell Transplantation 7Nivolumab 7Dexamethasone 7trametinib 6Radiotherapy 6Mesna 6Cytarabine 6Prednisone 5Calcium Dobesilate 5Bortezomib 5Azacitidine 5Alemtuzumab 5Voriconazole 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hematologic Neoplasms × Magnetic Resonance Imaging × Clear all
NCT05371054 2026-02-23

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
8 enrolled 20 charts
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡